Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Targeted protein drug firms announce partnerships, new leadership

by Gina Vitale
June 30, 2022 | A version of this story appeared in Volume 100, Issue 24

 

Generian Pharmaceuticals and Mitobridge, a subsidiary of Astellas Pharma, have formed a partnership to identify and develop small molecules that modulate undruggable protein targets in diseases with limited treatment options. Astellas will pay Generian up to $180 million and be responsible for clinical development. Separately, Dunad Therapeutics, a company focused on small-molecule protein degraders, has appointed Pearl Huang CEO. Huang has held leadership positions at Roche, GSK, Merck & Co., and, most recently, Cygnal Therapeutics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.